1. Pink Sheet

Sputnik V COVID-19 Vaccine Causing A Stir In The EU

No Special Inquiry Into Clinical Trials, Says EMA

 
• By Ian Schofield

The team behind Sputnik V has attacked what it calls “fake news and provocations” in the EU as political arguments over the vaccine claim another ministerial scalp.

Sputnik 5 vaccine against COVID-19. Glass medical vials with liquid on the background Sputnik V company logo
Russia's Sputnik V is not part of the EU's COVID-19 vaccine portfolio • Source: Alamy

Amid renewed concern over COVID-19 vaccine supplies following warnings by European regulators about the risk of rare blood clots with the Oxford/AstraZeneca PLC vaccine, EU countries are increasingly eyeing up the pros and cons of using Russia’s Sputnik V. But the vaccine is at the eye of a growing political storm.

Sputnik V is undergoing a rolling review at the European Medicines Agency pending the filing of a marketing authorization application...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Europe

More from Geography

EMA’s PRIME Scheme Explored: Growing Designations - But Are Accelerated Assessments Slipping?

 
• By Neena Brizmohun

While the first six months of the year saw eight new drugs targeting a range of diseases enter the European Medicines Agency’s priority medicines scheme, and three PRIME-designated treatments go on to win EU marketing approval, use of the accelerated assessment mechanism appears to be limited.

Global Pharma Guidance Tracker - June 2025

 
• By Vibha Sharma and Anabel Costa-Ferreira

Stay up to date on regulatory guidelines from around the world with the Pink Sheet’s Guidance Tracker. The complete Global Pharma Guidance Tracker, with sortable and searchable listings going back to 2014, is available online.

US FDA’s CRL Release More Incremental Than ‘Radical’ Transparency

 
• By Bridget Silverman

The transparency initiative collects CRLs already made public in approval packages on its drugs@fda site to post on the openFDA public portal.